این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
International Journal of Hematology-Oncology and Stem Cell Research، جلد ۱۶، شماره ۱، صفحات ۵۵-۶۵
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Survival of Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: An Experience in Developing Country
چکیده انگلیسی مقاله Background: Allogeneic stem cell transplantation (allo-SCT) is the highest potential treatment for long-term survival as post-remission therapy for acute myeloid leukemia (AML). The aim of this study was to estimate the overall survival (OS) of patients with AML after allo-SCT and to identify the factors affecting them as a prognostic factor for the survival of patients. Material and methods: In this retrospective cohort study, data of patients with AML who underwent allo-SCT at Taleghani bone marrow transplantation and cell therapy center in Tehran, Iran, from May 2009 to September 2016 were used. A total of 101 patients were enrolled and death time was considered a failure event for them. Kaplan-Meier method, log-Rank tests, and Cox proportional hazard model were used to evaluate OS and to identify the risk factors of patient’s survival. The SPSS software version 21 was used for the analysis of data and P< 0.05 was considered a significant level. Results: Of 101 patients with AML, 49 (48.5%) were males. The median age at allo-SCT was 32.76 years and 42 patients (41.6%) died. The 5-year OS and disease-free survival (DFS) was 56% (95%CI: 51-61%) and 52% (95%CI: 57-47%), respectively. Multivariate analysis by Cox regression indicated that OS has a significant relationship with WBC count and relapse (P=0.001).    Conclusion: Our results showed that allo–SCT has nearly the same outcome in developing countries and the WBC count and relapse are effective factors on the chance of survival in AML patients after allo-SCT.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله | Mahshid Mehdizadeh
Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran AND Taleghani Hospital Research Development Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran


| Vahid Bolourian
Department of Hematology and Medical Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran


| Maria Tavakoli-Ardakani
Department of Hematology and Medical Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran AND Pharmaceutical Science Research Center, Shahid Beheshti University of Medical Sciences


| Shayan Zamani
Tehran University of Medical Sciences, School of Medicine, Tehran, Iran


| Mahdi Tabarraee
Department of Hematology and Medical Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran


| Abbas Hajifathali
Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
نشانی اینترنتی https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1394
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات